Overview

* BioXcel Q3 2025 revenue and net income miss analyst expectations

* Company plans sNDA submission for BXCL501 in Q1 2026

* BioXcel advances late-stage clinical trials for BXCL501

Outlook

* BioXcel plans to submit an sNDA for IGALMI® in Q1 2026

* Company preparing for TRANQUILITY In-Care Phase 3 Trial

* BioXcel sees U.S. at-home agitation market at 57-77 mln episodes annually

Result Drivers

* R&D EXPENSES - Increased due to heightened clinical trial activity, particularly related to the SERENITY at-home Phase 3 studies

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $98,000 $216,000

Revenue (5

Analysts

)

Q3 Net Miss -$30.91 -$14.10

Income mln mln (5

Analysts

)

Q3 Basic Miss -$2.18 -$1.24

EPS (5

Analysts

)

Q3 Miss -$14.23 -$11.40

Operatin mln mln (4

g Income Analysts

)

Q3 $14.33

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for BioXcel Therapeutics Inc ( BTAI ) is $12.00, about 83.2% above its November 11 closing price of $2.02

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)